Blackrock Neurotech

What we’re able to do is the definition of a modern miracle-- we help people walk again. Talk again. Hear again. See again.   As the global leader in brain-computer interface (BCI) technology, Blackrock Neurotech has a simple mission: to restore human function and remedy neurological disease.   We’re the only chronic brain-computer interface (BCI)technology that is in patients now. As we look to the future, we have the potential to help millions of people affected by neurological disease and disabilities caused by paralysis, ALS, and spinal cord injuries. As the first to take the leap into human research, Blackrock Neurotech is the first BCI in humans and the only FDA-cleared platform for the neurological treatment of movement and direct-to-brain communications.  As the pioneer of this technology, Blackrock Neurotech intends to expand its applications with a simple, patient-centered focus: to make the technology work now, for the people who need it most.   Our mission is simple: We want people suffering from neurological disorders to walk, talk, see, hear, and feel again.

Blackrock Neurotech builds implantable neurotechnology with the mission of restoring human function and remedying neurological disease—to help people walk, talk, see, and hear again. For the first time in history, paralyzed individuals can operate objects in the physical world – simply by thinking. While this may sound like science fiction, it’s been a reality in clinical trials for more than two decades, thanks to our innovative neurotech design and engineering work. Our patients have already been able to move and feel again, type, make music, and even create art with our brain-computer interface technology. The future is bright – our devices have the opportunity to help more than 600 million patients living with physical disabilities from neurological disorders or spinal cord injuries improve mobility, communication, and independence; reduce their reliance on caregivers; and help them better engage with society and the world. The technology is also being used to explore applications such as ALS, sleep disturbances, circadian rhythms, chronic pain, depression, and more.   THE FUTURE VISION Ten years from now, neural implants could be as accessible as cardiac pacemakers are today -- offering patients a whole new world of opportunities to restore their independence. A major milestone in this vision is the release of MoveAgain, the first BCI platform to be commercially available to a broad patient population, which we expect to bring to market by the end of 2022. Beyond a commitment to helping people walk, talk, see, and hear again through our industry-leading BCI technology, we know that neurotechnology has the potential to exponentially increase quality of life and independence for people through a variety of applications. These therapeutic applications, which exist at the intersection of technology and biology, include paralysis, blindness, hearing loss, ALS, Parkinson’s, anxiety, and depression. In addition to BCIs, we build implantable tools and micro-electronics that diagnose and treat neurological disorders. We also provide research tools that have empowered thousands of published studies and groundbreaking innovations at hundreds of institutions around the world.